knowcompoundsmetformin
Specimen compound organic compoundPlate I
Metformin

- Formula
- C4H11N5
- Molar mass
- 129.167 g/mol
- ChEBI
- CHEBI:6801
- PubChem CID
- 4091
- InChIKey
- XZWYZXLIPXDOLR-UHFFFAOYSA-N
↓ lowered 5 findings in 3 endpoints
01 · the evidence, ordered
What the evidence says
- Strong
- 0
- Moderate
- 4
- Limited
- 0
- Very limited
- 1
- Insufficient
- 0
Metformin
Most findings
- All-cause mortality×2
- Body mass index×2
- Oesophageal cancer incidence×1
4 reference statements, not drawn · 36 compounds on the outer ring, not drawn
Keys
← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it
02 · findings
What metformin moved, and by how much
- OR odds ratio · MD mean difference. Brackets: the interval as reported.
- Dose studied: as its paper gave it.
- Evidence strength: computed from the study. How it is computed
5 shown
- All-cause mortalityMoved: lowersEvidence: Moderatereplicated ×1Paper: PMID 412080452026
- Who
- adults with type 2 diabetes undergoing noncardiac surgery, metformin users vs non-users; secondary endpoint, unadjusted (before IPTW weighting), five-year follow-up horizon
- Dose studied
- not reported
Before weighting, the 30-day and five-year mortalities after surgery were lower in the metformin group than in the non-metformin group (0.3% vs. 1.0%; P < 0.001 for 30-day mortality and 13.6% vs. 19.7%; P < 0.001 for five-year mortality).”
Quoted verbatim from Association of preoperative metformin use with postoperative mortality and morbidity in type 2 diabetes patients undergoing noncardiac surgery: a retrospective cohort study.cohortPermalink - All-cause mortalityMoved: lowersEffect, as reportedOR0.58[0.44 to 0.75]Evidence: Moderatereplicated ×1Paper: PMID 420878732026
- Who
- Adults with diabetes admitted with sepsis; pooled observational cohort studies comparing preadmission metformin users with non-users; mortality horizons pooled across studies (28-day, 30-day, 60-day, 90-day, 365-day, ICU and in-hospital)
- Dose studied
- not reported
The results of the meta-analysis with a random-effects model showed that septic patients who received metformin prior to hospitalization had significantly lower mortality compared to those without metformin use (OR, 0.58; 95% CI, 0.44–0.75, P < 0.00001).”
Quoted verbatim from Association of preadmission metformin use and prognosis in patients with sepsis with diabetes: a systematic review and meta-analysis.meta-analysisPermalink - Oesophageal cancer incidenceMoved: lowersEffect, as reportedOR0.87Evidence: ModeratePaper: PMID 397748292025
- Who
- Patients with diabetes; 12 observational studies (cohort and case-control) of metformin use versus non-use, pooled incidence of esophageal cancer
- Dose studied
- not reported
The random effects model showed that compared with the control groups, metformin might decrease EC incidence (OR = 0.87, P = 0.04).”
Quoted verbatim from Association of metformin use with risk and survival outcome of esophageal cancer in patients with diabetes: A systematic review and meta-analysis.meta-analysisPermalink - Body mass indexMoved: lowersEffect, as reportedMD−0.71[−1.23 to −0.19]Evidence: Moderatereplicated ×1Paper: PMID 405128732025
- Who
- Adults with type 1 diabetes on insulin, metformin versus placebo, each arm on standard insulin therapy; adult subgroup only, effect recorded at the 6-month timepoint (the sentence also reports a significant reduction at 3 months)
- Dose studied
- not reported
Metformin significantly reduced BMI among adults at three (MD = −1.56 [95% CI: −2.05, −1.08], p = 0.00, I 2 = 0.00%) and six (MD = −0.71 [95% CI: −1.23, −0.19], p = 0.01, I 2 = 66.28%) months.”
Quoted verbatim from An Updated Systematic Review and Meta-Analysis on the Efficacy and Safety of Metformin as Add-on Therapy to Insulin in Patients With Type 1 Diabetes.meta-analysisPermalink - Body mass indexMoved: lowersEvidence: Very limitedreplicated ×1Paper: PMID 395094162025
- Who
- Patients receiving second-generation antipsychotics with antipsychotic-induced weight gain, pooled from double-blind placebo-controlled trials
- Dose studied
- not reported
Additionally, metformin use resulted in a marked decrease in body mass index [-1.24 kg/m2 (95% CI: -1.70 to -0.77)].”
Quoted verbatim from The Optimal Dosage and Duration of Metformin for Prevention and Treatment of Antipsychotic-Induced Weight Gain: An Updated Systematic Review and Meta-Analysis.meta-analysisPermalink
No row matches these filters.
No dose is advised.
- OR odds ratio · MD mean difference. Brackets: the interval as reported.
- Dose studied: as its paper gave it.
- Evidence strength: computed from the study. How it is computed
03 · identity
Structure
- Charge
- 0
- SMILES
- CN(C)C(=N)NC(=N)N
04 · figures · 1 plate
Plates

fig. 5Metformin · MS2 [M+H]+ ESI-TOF positive · MassBank MSBNK-mFam-MC02_000764 (C. Broeckling, CC BY)
05 · reach
What it touches on the way
4 entities · assembled from reference reactions
Where it reaches
8 regions · transporter routes
- Female reproductivereproductive2 routesinferred
- Liverdigestive2 routesinferred
- Adrenal glandendocrine1 routeinferred
- Airway and sinusesrespiratory1 routeinferred
- Colon and rectumdigestive1 routeinferred
- Kidneyurinary1 routeinferred
- Lungrespiratory1 routeinferred
- Small intestinedigestive1 routeinferred
What the reference databases state
4Reference statements
What the reference databases state
Evidence keyStatements
4 statements
metformin is transported by each
- ProteinHuman-GEM MAR09583Inferred only
- ProteinHuman-GEM MAR09583Inferred only
- ProteinHuman-GEM MAR09584Inferred only
- ProteinHuman-GEM MAR09584Inferred only
3Reactions
07 · the record
Sources
3,678
papers screened for metformin
- admitted
- 5
- read and discarded
- 116
- not read yet
- 3,557
Sources cited
5 papers · 5 findings